WEKO3
アイテム
{"_buckets": {"deposit": "03ee3ffb-6b9f-4afb-b792-85e97e66d352"}, "_deposit": {"created_by": 6, "id": "27075", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "27075"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00027075", "sets": ["36"]}, "author_link": ["120692", "120687", "120694", "120688", "120690", "120686", "120691", "120689", "120693"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-01-07", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "art. no. 6", "bibliographicVolumeNumber": "50", "bibliographic_titles": [{"bibliographic_title": "Tropical Medicine and Health"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to emerge in 2020 and have been spreading globally during the coronavirus disease 2019 (COVID-19) pandemic. Despite the presence of different COVID-19 vaccines, the discovery of effective antiviral therapeutics for the treatment of patients infected with SARS-CoV-2 are still urgently needed. A natural amino acid, 5-aminolevulinic acid (5-ALA), has exhibited both antiviral and anti-inflammatory activities. In a previous study, we demonstrated an in vitro antiviral effect of 5-ALA against SARS-CoV-2 infection without significant cytotoxicity. In the present study, we sought to investigate whether 5-ALA with or without sodium ferrous citrate (SFC) can inhibit in vitro both the original SARS-CoV-2 Wuhan strain and its variants, including the Alpha, Beta, Gamma and Delta strains.\nMethods: The antiviral activity of ALA with or without SFC was determined in Vero-E6 cell. The virus inhibition was quantified by real time RT-PCR.\nResults: Co-administration of 5-ALA and SFC inhibited the Wuhan, Alpha and Delta variants of SARS-CoV-2 with IC50 values of 235, 173 and 397 µM, respectively, and the Beta and Gamma variants with IC50 values of 1311 and 1516 µM.\nConclusion: Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Tropical Medicine and Health, 50, art. no. 6; 2022", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "BioMed Central Ltd"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1186/s41182-021-00397-x", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1349-4147", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ngwe Tun, Mya Myat"}], "nameIdentifiers": [{"nameIdentifier": "120686", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakura, Takaya"}], "nameIdentifiers": [{"nameIdentifier": "120687", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakurai, Yasuteru"}], "nameIdentifiers": [{"nameIdentifier": "120688", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurosaki, Yohei"}], "nameIdentifiers": [{"nameIdentifier": "120689", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inaoka, Daniel Ken"}], "nameIdentifiers": [{"nameIdentifier": "120690", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shioda, Norifumi"}], "nameIdentifiers": [{"nameIdentifier": "120691", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuda, Jiro"}], "nameIdentifiers": [{"nameIdentifier": "120692", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kita, Kiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "120693", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morita, Kouichi"}], "nameIdentifiers": [{"nameIdentifier": "120694", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-02-09"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "TMH50_6.pdf", "filesize": [{"value": "846.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 846900.0, "url": {"label": "TMH50_6.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/27075/files/TMH50_6.pdf"}, "version_id": "418d2517-af3e-4476-a400-c9f295cf6d97"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "SARS-CoV-2 variants", "subitem_subject_scheme": "Other"}, {"subitem_subject": "5-ALA", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SFC", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Anti-viral drug", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2"}]}, "item_type_id": "2", "owner": "6", "path": ["36"], "permalink_uri": "http://hdl.handle.net/10069/00041239", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-02-09"}, "publish_date": "2022-02-09", "publish_status": "0", "recid": "27075", "relation": {}, "relation_version_is_last": true, "title": ["Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2"], "weko_shared_id": -1}
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2
http://hdl.handle.net/10069/00041239
http://hdl.handle.net/10069/00041239e81ae01c-0b40-44b6-a43f-65bf3544501a
名前 / ファイル | ライセンス | アクション |
---|---|---|
TMH50_6.pdf (846.9 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-02-09 | |||||
タイトル | ||||||
タイトル | Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SARS-CoV-2 variants | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 5-ALA | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SFC | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Anti-viral drug | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ngwe Tun, Mya Myat
× Ngwe Tun, Mya Myat× Sakura, Takaya× Sakurai, Yasuteru× Kurosaki, Yohei× Inaoka, Daniel Ken× Shioda, Norifumi× Yasuda, Jiro× Kita, Kiyoshi× Morita, Kouichi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to emerge in 2020 and have been spreading globally during the coronavirus disease 2019 (COVID-19) pandemic. Despite the presence of different COVID-19 vaccines, the discovery of effective antiviral therapeutics for the treatment of patients infected with SARS-CoV-2 are still urgently needed. A natural amino acid, 5-aminolevulinic acid (5-ALA), has exhibited both antiviral and anti-inflammatory activities. In a previous study, we demonstrated an in vitro antiviral effect of 5-ALA against SARS-CoV-2 infection without significant cytotoxicity. In the present study, we sought to investigate whether 5-ALA with or without sodium ferrous citrate (SFC) can inhibit in vitro both the original SARS-CoV-2 Wuhan strain and its variants, including the Alpha, Beta, Gamma and Delta strains. Methods: The antiviral activity of ALA with or without SFC was determined in Vero-E6 cell. The virus inhibition was quantified by real time RT-PCR. Results: Co-administration of 5-ALA and SFC inhibited the Wuhan, Alpha and Delta variants of SARS-CoV-2 with IC50 values of 235, 173 and 397 µM, respectively, and the Beta and Gamma variants with IC50 values of 1311 and 1516 µM. Conclusion: Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants. |
|||||
書誌情報 |
Tropical Medicine and Health 巻 50, p. art. no. 6, 発行日 2022-01-07 |
|||||
出版者 | ||||||
出版者 | BioMed Central Ltd | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1349-4147 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1186/s41182-021-00397-x | |||||
権利 | ||||||
権利情報 | © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Tropical Medicine and Health, 50, art. no. 6; 2022 |